Equities
Health CarePharmaceuticals and Biotechnology
  • Price (GBX)287.00
  • Today's Change-7.50 / -2.55%
  • Shares traded168.59k
  • 1 Year change+1.95%
  • Beta0.9778
Data delayed at least 20 minutes, as of Dec 06 2022 16:49 GMT.
More ▼
Take Action
Take Action
Add this security to watchlist, portfolio, or create an alert to track market movement

Profile data is unavailable for this security.

About the company

PureTech Health plc (PureTech) is a biotherapeutics company engaged in the treatment paradigm for devastating diseases. The Company has created a pipeline through its experienced research and development team and its network of scientists, clinicians, and industry leaders. The pipeline, which is being advanced both internally and through PureTech's Founded Entities, is comprised of 27 therapeutics and therapeutic candidates, including two that have received both United States (U.S.) Food and Drug Administration (FDA) clearance and European marketing authorization. All of the underlying programs and platforms that resulted in the pipeline of therapeutic candidates are identified or discovered and then advanced by the PureTech team through key validation points based on insights in immunology and drug development. The Company's wholly owned pipeline consists of various programs, including LYT-100, LYT-200, LYT-210, LYT-300, LYT-500, LYT-510, and LYT-503/IMB-150.

  • Revenue in GBP (TTM)15.25m
  • Net income in GBP-11.08m
  • Incorporated2015
  • Employees95.00
  • Location
    PureTech Health PLC6 Tide Street, Suite 400BOSTON 02210United StatesUSA
  • Phone+1 (617) 482-2333
  • Fax+1 (617) 482-3337
  • Websitehttp://puretechhealth.com/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Scancell Holdings Plc0.00-2.07m190.76m40.00--10.53-----0.0027-0.00270.000.02220.00----0.00-4.72-31.06-4.99-33.18------------0.3111------86.66--83.42--
Bioventix PLC11.72m7.67m191.18m17.0025.1516.1724.4616.311.461.462.232.270.90061.792.38--58.9853.9264.5957.7593.9492.5565.4864.969.07----76.927.2210.0914.019.29-11.5319.83
Faron Pharmaceuticals Oy0.00-20.46m193.57m37.00---------0.389-0.3890.00-0.08090.00----0.00-166.26-165.50-342.16-391.61-------487,178.90----1.73-------25.16--38.80--
Redx Pharma PLC16.29m-18.62m204.30m71.00--31.21--12.54-0.0679-0.06790.05940.01950.38--46.40229,394.40-43.45-40.30-63.41-66.57-----114.35-85.78---10.980.7683--76.52---134.19--11.17--
Alliance Pharma plc163.34m12.18m247.32m250.0020.560.832510.781.510.02230.02230.30180.55010.30752.374.68640,560.802.294.232.504.8266.4263.247.4613.501.4713.440.314539.3325.7410.85-8.82-16.5631.706.92
Avacta Group Plc6.14m-25.17m284.45m133.00--7.55--46.35-0.1005-0.09610.02450.14170.11612.050.981846,142.86-47.59---52.99--59.26---410.09--4.96-38.040.1183--37.17---60.85------
Oxford BioMedica plc125.57m-24.54m401.42m959.00--1.62--3.20-0.262-0.2621.392.580.3784.452.52154,076.10-8.04-0.756-11.40-0.997660.4355.20-21.26-1.201.71-11.230.2925--62.7738.74404.42--7.94--
Ergomed PLC132.46m13.36m671.27m1.26k50.798.8935.875.070.26340.26342.621.501.22--4.60105,542.6012.334.2718.566.1340.9741.1810.083.85--53.130.03330.0037.2624.7630.90---2.38--
Puretech Health PLC15.25m-11.08m827.04m95.00--1.79--54.25-0.0384-0.03840.0531.660.0216--4.76160,485.90-1.004.86-1.266.24-----46.43260.53----0.07710.0047.7631.45-1,111.83--9.02--
Genus plc593.40m40.90m2.01bn3.33k48.953.4726.523.380.62350.62359.048.800.635--5.04178,466.203.933.234.643.80----6.185.041.37113.600.281267.183.335.27-13.534.5128.186.28
Worldwide Healthcare Trust PLC-59.72m-84.06m2.14bn0.00--0.9378-----1.28-1.28-0.914935.51-0.0233-------3.287.07-3.577.52--86.92--84.78----0.0010.32-125.52---129.67----3.33
Indivior PLC724.48m136.20m2.37bn802.0018.8412.8114.963.270.91950.91954.891.350.52391.524.77903,346.409.856.9817.3414.2682.5686.3218.8012.431.5610.560.54870.0022.26-5.65238.5142.41-0.5781--
Data as of Dec 06 2022. Currency figures normalised to PureTech Health PLC's reporting currency: UK Pound GBX

Institutional shareholders

61.80%Per cent of shares held by top holders
HolderShares% Held
Invesco Asset Management Ltd.as of 07 Oct 202264.58m23.16%
Lansdowne Partners (UK) LLPas of 10 Oct 202225.36m9.09%
Baillie Gifford & Co.as of 07 Oct 202221.02m7.54%
Jupiter Asset Management Ltd.as of 15 Jul 202014.25m5.11%
M&G Investment Management Ltd.as of 07 Oct 202212.54m4.50%
Miller Value Partners LLCas of 31 Mar 202110.04m3.60%
Eurizon Capital SGR SpAas of 01 Nov 20229.56m3.43%
Hargreave Hale Ltd.as of 07 Oct 20225.34m1.92%
Canaccord Genuity Wealth Ltd.as of 01 Nov 20225.15m1.85%
DNCA Finance SAas of 30 Jun 20224.50m1.61%
More ▼
Data from 30 Sep 2022 - 30 Nov 2022Source: FactSet Research Systems Inc.
An LSEG Business
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.